Please note that the ANZCTR website will be unavailable from 9am until 9.30am (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00480025




Registration number
NCT00480025
Ethics application status
Date submitted
29/05/2007
Date registered
30/05/2007
Date last updated
25/06/2019

Titles & IDs
Public title
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Scientific title
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Secondary ID [1] 0 0
2007-001283-73
Secondary ID [2] 0 0
109493
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lung Cancer, Non-Small Cell 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - GSK1572932A Antigen-Specific Cancer Immunotherapeutic
Other interventions - Placebo Control

Experimental: ASCI Group -

Placebo Comparator: Placebo Group -


Other interventions: GSK1572932A Antigen-Specific Cancer Immunotherapeutic
Intramuscular administration, 13 doses

Other interventions: Placebo Control
Intramuscular administration, 13 doses

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the Overall Population - DFS = time interval from randomization to 1st evidence of recurrence/death, if occurring before. All recurrence types were included, including local, regional & distant metastasis & 2nd primary lung cancer (i.e. local recurrence, defined as a tumor within same lung or at bronchial stump; regional recurrence, involving a clinically or radiologically manifest disease in mediastinum or supraclavicular nodes; & distant recurrence [any tumor arising in contralateral lung or outside hemithorax]). Deaths occurring without prior documentation of recurrence were considered as event & not censored. If no event occurred by time of analysis, time to event was censored at last assessment date of patient. New 1ry cancers outside lungs were not considered as event. PYAR= n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median DFS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [1] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Primary outcome [2] 0 0
Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the No-CT Population - DFS = time interval from randomization to 1st evidence of recurrence/death, if occurring before. All recurrence types were included, including local, regional & distant metastasis & 2nd primary lung cancer (i.e. local recurrence, defined as a tumor within same lung or at bronchial stump; regional recurrence, involving a clinically or radiologically manifest disease in mediastinum or supraclavicular nodes; & distant recurrence [any tumor arising in contralateral lung or outside hemithorax]). Deaths occurring without prior documentation of recurrence were considered as event & not censored. If no event occurred by time of analysis, time to event was censored at last assessment date of patient. New 1ry cancers outside lungs were not considered as event. PYAR= n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median DFS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [2] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [1] 0 0
Person Year Rate (PYAR) as Regards Overall-survival (OS) in the Overall Population - OS was defined as the time interval from randomization to the date of death, irrespective of the cause of death. Patients still alive were censored at the last visit they were known to be alive. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median OS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [1] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [2] 0 0
Person Year Rate (PYAR) as Regards Overall-survival (OS) in the No-CT Population - OS was defined as the time interval from randomization to the date of death, irrespective of the cause of death. Patients still alive were censored at the last visit they were known to be alive. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median OS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [2] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [3] 0 0
Person Year Rate (PYAR) as Regards Overall-survival (OS) in the CT Population - OS was defined as the time interval from randomization to the date of death, irrespective of the cause of death. Patients still alive were censored at the last visit they were known to be alive. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median OS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [3] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [4] 0 0
Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the Overall Population - LCSS was defined as the time interval from randomization to the date of death due to lung cancer. Deaths due to other or unknown causes were censored at the date of death. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median OS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [4] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [5] 0 0
Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the No-CT Population - LCSS was defined as the time interval from randomization to the date of death due to lung cancer. Deaths due to other or unknown causes were censored at the date of death. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median OS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [5] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [6] 0 0
Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the CT Population - DFS = time interval from randomization to 1st evidence of recurrence/death, if occurring before. All recurrence types were included, including local, regional & distant metastasis & 2nd primary lung cancer (i.e. local recurrence, defined as a tumor within same lung or at bronchial stump; regional recurrence, involving a clinically or radiologically manifest disease in mediastinum or supraclavicular nodes; & distant recurrence [any tumor arising in contralateral lung or outside hemithorax]). Deaths occurring without prior documentation of recurrence were considered as event & not censored. If no event occurred by time of analysis, time to event was censored at last assessment date of patient. New 1ry cancers outside lungs were not considered as event. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median DFS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [6] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [7] 0 0
Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the CT Population - LCSS was defined as the time interval from randomization to the date of death due to lung cancer. Deaths due to other or unknown causes were censored at the date of death. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median OS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [7] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [8] 0 0
Kaplan-Meier Estimate (KME) of 2, 3, 4 and 5-year as Regards Disease-free Survival (DFS) in the Overall Population - DFS = time interval from randomization to 1st evidence of recurrence/death, if occurring before. All recurrence types were included, including local, regional & distant metastasis & 2nd primary lung cancer (i.e. local recurrence, defined as a tumor within same lung or at bronchial stump; regional recurrence, involving a clinically or radiologically manifest disease in mediastinum or supraclavicular nodes; & distant recurrence [any tumor arising in contralateral lung or outside hemithorax]). Deaths occurring without prior documentation of recurrence were considered as event & not censored. If no event occurred by time of analysis, time to event was censored at last assessment date of patient. New 1ry cancers outside lungs were not considered as event. Median DFS KMEs in % were obtained non-parametrically by Kaplan-Meier method and confidence intervals (CIs) calculated using the Greenwood formula for standard error computation.
Timepoint [8] 0 0
KME assessed at 2, 3, 4 and 5-year (Y) post Dose 1 of treatment. Follow-up period was from administration of 1st dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [9] 0 0
Kaplan-Meier Estimate (KME) of 2, 3, 4 and 5-year as Regards Disease-free Survival (DFS) in the No-CT Population - DFS = time interval from randomization to 1st evidence of recurrence/death, if occurring before. All recurrence types were included, including local, regional & distant metastasis & 2nd primary lung cancer (i.e. local recurrence, defined as a tumor within same lung or at bronchial stump; regional recurrence, involving a clinically or radiologically manifest disease in mediastinum or supraclavicular nodes; & distant recurrence [any tumor arising in contralateral lung or outside hemithorax]). Deaths occurring without prior documentation of recurrence were considered as event & not censored. If no event occurred by time of analysis, time to event was censored at last assessment date of patient. New 1ry cancers outside lungs were not considered as event. Median DFS KMEs in % were obtained non-parametrically by Kaplan-Meier method and confidence intervals (CIs) calculated using the Greenwood formula for standard error computation.
Timepoint [9] 0 0
KME assessed at 2, 3, 4 and 5-year (Y) post Dose 1 of treatment Follow-up period was from administration of 1st dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [10] 0 0
Kaplan-Meier Estimate (KME) of 2, 3, 4 and 5-year as Regards Disease-free Survival (DFS) in the CT Population - DFS = time interval from randomization to 1st evidence of recurrence/death, if occurring before. All recurrence types were included, including local, regional & distant metastasis & 2nd primary lung cancer (i.e. local recurrence, defined as a tumor within same lung or at bronchial stump; regional recurrence, involving a clinically or radiologically manifest disease in mediastinum or supraclavicular nodes; & distant recurrence [any tumor arising in contralateral lung or outside hemithorax]). Deaths occurring without prior documentation of recurrence were considered as event & not censored. If no event occurred by time of analysis, time to event was censored at last assessment date of patient. New 1ry cancers outside lungs were not considered as event. Median DFS KMEs in % were obtained non-parametrically by Kaplan-Meier method and confidence intervals (CIs) calculated using the Greenwood formula for standard error computation.
Timepoint [10] 0 0
KME assessed at 2, 3, 4 and 5-year (Y) post Dose 1 of treatment. Follow-up period was from administration of 1st dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [11] 0 0
Person Year Rate (PYAR) as Regards Disease-free Specific Survival (DFSS) in the Overall Population - DFSS was defined as the interval from randomization to the date of disease recurrence or death due to lung cancer. Patients who had died due to another cause than lung cancer were censored on their date of death and patients alive at the time of analysis were censored on the date of last assessment. Patients with no assessment post-randomization were censored on the date of randomization. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median DFS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [11] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [12] 0 0
Person Year Rate (PYAR) as Regards Disease-free Specific Survival (DFSS) in the No-CT Population - DFSS was defined as the interval from randomization to the date of disease recurrence or death due to lung cancer. Patients who had died due to another cause than lung cancer were censored on their date of death and patients alive at the time of analysis were censored on the date of last assessment. Patients with no assessment post-randomization were censored on the date of randomization. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median DFS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [12] 0 0
From administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [13] 0 0
Person Year Rate (PYAR) as Regards Disease-free Specific Survival (DFSS) in the CT Population - DFSS was defined as the interval from randomization to the date of disease recurrence or death due to lung cancer. Patients who had died due to another cause than lung cancer were censored on their date of death and patients alive at the time of analysis were censored on the date of last assessment. Patients with no assessment post-randomization were censored on the date of randomization. PYAR = n (number of subjects reported with at least 1 event) divided by T (sum of follow-up period [in years] censored at 1st occurrence of event in group). Median DFS estimates were obtained non-parametrically by Kaplan-Meier method.
Timepoint [13] 0 0
Period of follow-up was from administration of first dose of GSK1572932 study product/placebo solution to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [14] 0 0
Number of Subjects Seropositive for Anti-Melanoma AntiGEn (MAGE)-A3 Antibodies (Anti-MAGE-A3 S+) - A seropositive subject for anti-MAGE-A3 antibodies was a subject with anti-MAGE-A3 antibodies >= the seropositivity cut-off of 27 Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL).
Timepoint [14] 0 0
Pre-treatment (PRE), at Weeks (W) 6 and 12, at Months (M) 9, 12, 18 and 30 and at one year after treatment concluding time point, i.e. at follow-up visit 2 at W120 added of one year (At 12M post W120)
Secondary outcome [15] 0 0
Number of Humoral Responders as Regards Anti-Melanoma AntiGEn (MAGE)-A3 Antibodies (Anti-MAGE-A3 HR) - A seropositive/seronegative subject for anti-MAGE-A3 antibodies was a subject with anti-MAGE-A3 antibodies >=/< the seropositivity cut-off of 27 Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL). A humoral responder as regards anti-MAGE-A3 antibodies was defined as 1) for initially seronegative patients, a patient with post-administration Anti-MAGE-A3 antibody concentration >= 27 EL.U/mL; 2) for initially seropositive patients: post-treatment administration antibody concentration >= 2 fold the pre-treatment antibody concentration.
Timepoint [15] 0 0
At Weeks (W) 6 and 12, at Months (M) 9, 12, 18 and 30 and at one year after treatment concluding time point, i.e. at follow-up visit 2 at W120 added of one year (at 12M post W120)
Secondary outcome [16] 0 0
Number of Subjects Seropositive for Anti-protein D (PD) Antibodies (Anti-PD S+) - A seropositive subject for anti-PD antibodies was a subject with anti-PD antibodies >= the seropositivity cut-off of 100 Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL).
Timepoint [16] 0 0
Pre-treatment (PRE), at Weeks (W) 6 and 12, at Months (M) 9, 12, 18 and 30 and at one year after treatment concluding time point, i.e. at follow-up visit 2 at W120 added of one year (at 12M post W120)
Secondary outcome [17] 0 0
Number of Humoral Responders as Regards Anti-protein D (PD) Antibodies (Anti-PD HR) - A seropositive/seronegative subject for anti-PD antibodies was a subject with anti-PD antibodies =/< the seropositivity cut-off of 100 Enzyme-linked immunosorbent assay (ELISA) units per millilitre (EL.U/mL). A humoral responder as regards anti-PD antibodies was defined as 1) for initially seronegative patients, a patient with post-administration anti-PD antibody concentration = 100 EL.U/mL; 2) for initially seropositive patients: post-administration antibody concentration = 2 fold the pre-vaccination antibody concentration.
Timepoint [17] 0 0
At Weeks (W) 6 and 12, at Months (M) 9, 12, 18 and 30 and at one year after treatment concluding time point, i.e. at follow-up visit 2 at W120 added of one year (at 12M post W120)
Secondary outcome [18] 0 0
Health-related Quality of Life (HQL) Scores - HQL was assessed using the EQ-5D generic health state classification and valuation system. The number and percentage of patients with each score within each dimension of the EQ-5D questionnaire (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) were tabulated at each assessment for each group. Each of these scores can take 3 levels: no problem (level 1), moderate problem (level 2) or extreme problem (level 3). Resulting descriptive mean and standard deviation (SD) for the EQ-5D Utility Value (EQ-5D UV) were tabulated. Valid EQ-5D data were defined as questionnaires assessed 1) on day of and before treatment administration; or 2) on day after treatment administration for W0, W6, W12; or 3)during follow-up visits or at time of recurrence. The EQ-5D total score ranges from -0.016 (worst health state) to 1.000 (best health state).
Timepoint [18] 0 0
At Week (W) 0 on day of treatment (DoT) (W0 DoT), W0 on day post treatment (DpT) (W0 DpT), W6 DoT, W6 DpT, W12 DoT, W12 DpT, Month (M) 6, M9, M12, M24, 6M post W120, at recurrence, and at 12M post W120
Secondary outcome [19] 0 0
Number of Patients With Abnormal Alanine Aminotransferase (ALT) Values by Maximum Grade - The status of each patient as regards ALT laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0), G1 and G2. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [19] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [20] 0 0
Number of Patients With Abnormal Alanine Aspartate Aminotransferase (AST) Values by Maximum Grade - The status of each patient as regards AST laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0), G1 and G2. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [20] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [21] 0 0
Number of Patients With Abnormal Alkaline Phosphatase (ALKP) Values by Maximum Grade - The status of each patient as regards ALKP laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0), G1 and G2. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [21] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [22] 0 0
Number of Patients With Abnormal Bilirubin (BIL) Values by Maximum Grade - The status of each patient as regards BIL laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0) and G1. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [22] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [23] 0 0
Number of Patients With Abnormal Creatinine (CREA) Values by Maximum Grade - The status of each patient as regards CREA laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0), G1 and G2. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [23] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [24] 0 0
Number of Patients With Abnormal Haemoglobin (HGB) Values by Maximum Grade - The status of each patient as regards HGB laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0), G1, G2 and G3. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [24] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [25] 0 0
Number of Patients With Abnormal Leukocytes (LEU) Values by Maximum Grade - The status of each patient as regards LEU laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0), G1, G2 and G3. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [25] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [26] 0 0
Number of Patients With Abnormal Lymphocytes (LYM) Values by Maximum Grade - The status of each patient as regards LYM laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0), G1, G2 and G3. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [26] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [27] 0 0
Number of Patients With Abnormal Neutrophils (NEU) Values by Maximum Grade - The status of each patient as regards NEU laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0), G1, G2, G3 and G4. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [27] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [28] 0 0
Number of Patients With Abnormal Platelets (PLA) Values by Maximum Grade - The status of each patient as regards PLA laboratory values at baseline (SCR) up to DLP was collected and graded according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. The post-treatment values were presented by worst grade versus baseline grade. SCR CTC grade statuses reported were unknown (UNK), Grade 0 (G0), G1 and G3. CTC grade statuses reported at DLP were G0, G1, G2, G3, G4, and UNK.
Timepoint [28] 0 0
From screening (SCR) to data lock point (DLP) on 23 January 2014 (up to 5 years per patient)
Secondary outcome [29] 0 0
Number of Patients With Any Adverse Events (AEs) and With AEs by Maximum Grade Reported - Up to Data Lock Point (DLP) - An AE was any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs reported are here below tabulated irrespective of grade, as well as graded by maximum grade reported according to the Common Terminology Criteria (CTC) Adverse event terminology, version 3.0. Maximum grade reported and tabulated were Grade 1 (G1), G2, G3, G4 and G5. Any here below is defined as irrespective of CTC grade reported.
Timepoint [29] 0 0
Within the 31-day follow-up period post treatment administration, up to data lock point (DLP) on 23 January 2014 (up to 2.5 years per patient)
Secondary outcome [30] 0 0
Number of Patients With Serious Adverse Events (SAEs) - Up to Data Lock Point (DLP) - A SAE is any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study subject, or was a Grade 4 AE according to CTC for Adverse Events, Version 3.0. Events part of natural course of lung cancer (i.e., disease progression, recurrence) were captured towards clinical efficacy assessment (CEA) and were not reported as SAEs. Death due to a progressive disease was similarly recorded towards CEA, but not as an SAE. However, if progression of lung cancer disease was greater than normally be expected, or if investigators considered that there was a causal relationship between treatment or protocol design/procedures and disease progression/ recurrence, then it was reported as SAE. Any new cancer (non-related to lung cancer) was reported as SAE.
Timepoint [30] 0 0
From screening (SCR) up to data lock point (DLP) on 23 January 2014 (up to 2.5 years per patient)

Eligibility
Key inclusion criteria
Inclusion criteria:

- Male or female patient with completely resected, pathologically proven stage IB, II or
IIIA NSCLC.

- Written informed consent for MAGE-A3 expression screening on tumor biopsy has been
obtained from the patient prior to shipment of the sample for expression testing
(before or just after surgical resection), and written informed consent for the
complete study has been obtained prior to the performance of any other
protocol-specific procedure.

- Patient is = 18 years of age at the time of signature of the first informed consent
form.

- The patient's tumor shows expression of MAGE-A3 gene

- The surgical technique for resection of the patient's tumor is anatomical, involving
at least a lobectomy or a sleeve lobectomy;

- The mediastinal lymph node sampling is done according to study protocol guidelines;

- The patient is free of metastasis, as confirmed by a negative baseline computer
tomogram (CT scan) of the chest, upper abdomen and CT scan or MRI of the brain.

Other examinations should be performed as clinically indicated. Note that if randomization
is taking place within 8 weeks after surgery, brain CT scans or brain MRI performed up to 4
weeks before surgery do not have to be repeated.

- ECOG performance status of 0, 1 or 2 at the time of randomization.

- Adequate bone-marrow reserve, adequate renal function and adequate hepatic function as
assessed by standard laboratory criteria, and defined as:

Absolute neutrophil count = 1.0 x 10E9/L Platelet count = 75 x 10E9/L Serum creatinine =
1.5 times the Upper Limit of Normal (ULN)

= 3.0 times the ULN if due to platinum adjuvant chemotherapy Total bilirubin = 1.5 times
the ULN Alanine transaminase (ALAT) = 2.5 times the ULN

- If the patient is female, she must be of non-childbearing potential, i.e. have a
current tubal ligation, hysterectomy, ovariectomy or be post menopausal, or if she is
of childbearing potential, she must practice adequate contraception for 30 days prior
to administration of study treatment, have a negative pregnancy test and continue such
precautions during all study treatment period and for 2 months after completion of the
injection series.

- In the view of the investigator, the patient can and will comply with the requirements
of the protocol.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria

- The primary tumor was removed by segmentectomy or wedge resection.

- The patient shows any evidence of residual tumor after surgery.

- The patient has received any anti-cancer specific treatment, including radiotherapy,
immunotherapy, chemotherapy or neo-adjuvant chemotherapy, except:

For the treatment of previous malignancies as allowed by the protocol (i.e., non-melanoma
skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has
been in remission for over 5 years), Administration of adjuvant platinum-based chemotherapy
for the treatment of the current NSCLC is allowed between surgery and randomization.

- The patient has previous or concomitant malignancies at other sites, except
effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or
effectively treated malignancy that has been in remission for over 5 years and highly
likely to have been cured.

- History of allergic disease or reactions likely to be exacerbated by any component of
the study investigational product.

- The patient has an autoimmune disease such as, but not limited to, multiple sclerosis,
lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.

- The patient requires concomitant treatment with systemic corticosteroids, or any other
immunosuppressive agents.

Note: The use of prednisone, or equivalent, <0.5 mg/kg/day (absolute maximum 40 mg/day), or
inhaled corticosteroids for COPD or topical steroids is permitted.

- The patient has received a major organ allograft.

- The patient is known to be HIV-positive.

- The patient has an uncontrolled bleeding disorder.

- The patient has uncontrolled congestive heart failure or hypertension, unstable heart
disease (coronary artery disease or myocardial infarction) or uncontrolled arrhythmia
at the time of enrolment.

- The patient needs home oxygenation.

- The patient has psychiatric or addictive disorders that may compromise his/her ability
to give informed consent, or to comply with the trial procedures.

- The patient has other concurrent severe medical problems, unrelated to the malignancy,
that would significantly limit full compliance with the study or expose the patient to
unacceptable risk.

- The patient has received any investigational or non-registered medicinal product other
than the study medication within the 30 days preceding the first dose of study
medication, or plans to receive such a drug during the study period.

- For female patients: the patient is pregnant or lactating.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Garran
Recruitment hospital [2] 0 0
GSK Investigational Site - Camperdown
Recruitment hospital [3] 0 0
GSK Investigational Site - Tweed Heads
Recruitment hospital [4] 0 0
GSK Investigational Site - Waratah
Recruitment hospital [5] 0 0
GSK Investigational Site - Westmead
Recruitment hospital [6] 0 0
GSK Investigational Site - Chermside
Recruitment hospital [7] 0 0
GSK Investigational Site - South Brisbane
Recruitment hospital [8] 0 0
GSK Investigational Site - Woolloongabba
Recruitment hospital [9] 0 0
GSK Investigational Site - Adelaide
Recruitment hospital [10] 0 0
GSK Investigational Site - Hobart
Recruitment hospital [11] 0 0
GSK Investigational Site - Box Hill
Recruitment hospital [12] 0 0
GSK Investigational Site - Fitzroy
Recruitment hospital [13] 0 0
GSK Investigational Site - Heidelberg
Recruitment hospital [14] 0 0
GSK Investigational Site - Richmond
Recruitment hospital [15] 0 0
GSK Investigational Site - Nedlands
Recruitment hospital [16] 0 0
GSK Investigational Site - Perth
Recruitment postcode(s) [1] 0 0
2606 - Garran
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
2485 - Tweed Heads
Recruitment postcode(s) [4] 0 0
2298 - Waratah
Recruitment postcode(s) [5] 0 0
2145 - Westmead
Recruitment postcode(s) [6] 0 0
4032 - Chermside
Recruitment postcode(s) [7] 0 0
4101 - South Brisbane
Recruitment postcode(s) [8] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [9] 0 0
5000 - Adelaide
Recruitment postcode(s) [10] 0 0
7000 - Hobart
Recruitment postcode(s) [11] 0 0
3128 - Box Hill
Recruitment postcode(s) [12] 0 0
3065 - Fitzroy
Recruitment postcode(s) [13] 0 0
3084 - Heidelberg
Recruitment postcode(s) [14] 0 0
3121 - Richmond
Recruitment postcode(s) [15] 0 0
6009 - Nedlands
Recruitment postcode(s) [16] 0 0
6001 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Delaware
Country [8] 0 0
United States of America
State/province [8] 0 0
District of Columbia
Country [9] 0 0
United States of America
State/province [9] 0 0
Florida
Country [10] 0 0
United States of America
State/province [10] 0 0
Georgia
Country [11] 0 0
United States of America
State/province [11] 0 0
Hawaii
Country [12] 0 0
United States of America
State/province [12] 0 0
Idaho
Country [13] 0 0
United States of America
State/province [13] 0 0
Illinois
Country [14] 0 0
United States of America
State/province [14] 0 0
Indiana
Country [15] 0 0
United States of America
State/province [15] 0 0
Iowa
Country [16] 0 0
United States of America
State/province [16] 0 0
Kentucky
Country [17] 0 0
United States of America
State/province [17] 0 0
Louisiana
Country [18] 0 0
United States of America
State/province [18] 0 0
Maryland
Country [19] 0 0
United States of America
State/province [19] 0 0
Massachusetts
Country [20] 0 0
United States of America
State/province [20] 0 0
Michigan
Country [21] 0 0
United States of America
State/province [21] 0 0
Minnesota
Country [22] 0 0
United States of America
State/province [22] 0 0
Missouri
Country [23] 0 0
United States of America
State/province [23] 0 0
Montana
Country [24] 0 0
United States of America
State/province [24] 0 0
Nebraska
Country [25] 0 0
United States of America
State/province [25] 0 0
Nevada
Country [26] 0 0
United States of America
State/province [26] 0 0
New Hampshire
Country [27] 0 0
United States of America
State/province [27] 0 0
New Jersey
Country [28] 0 0
United States of America
State/province [28] 0 0
New York
Country [29] 0 0
United States of America
State/province [29] 0 0
North Carolina
Country [30] 0 0
United States of America
State/province [30] 0 0
Ohio
Country [31] 0 0
United States of America
State/province [31] 0 0
Oklahoma
Country [32] 0 0
United States of America
State/province [32] 0 0
Oregon
Country [33] 0 0
United States of America
State/province [33] 0 0
Pennsylvania
Country [34] 0 0
United States of America
State/province [34] 0 0
Rhode Island
Country [35] 0 0
United States of America
State/province [35] 0 0
South Carolina
Country [36] 0 0
United States of America
State/province [36] 0 0
Tennessee
Country [37] 0 0
United States of America
State/province [37] 0 0
Texas
Country [38] 0 0
United States of America
State/province [38] 0 0
Utah
Country [39] 0 0
United States of America
State/province [39] 0 0
Virginia
Country [40] 0 0
United States of America
State/province [40] 0 0
Washington
Country [41] 0 0
United States of America
State/province [41] 0 0
Wisconsin
Country [42] 0 0
Argentina
State/province [42] 0 0
Buenos Aires
Country [43] 0 0
Argentina
State/province [43] 0 0
Córdova
Country [44] 0 0
Argentina
State/province [44] 0 0
Río Negro
Country [45] 0 0
Argentina
State/province [45] 0 0
Santa Fe
Country [46] 0 0
Argentina
State/province [46] 0 0
Quilmes
Country [47] 0 0
Argentina
State/province [47] 0 0
Tucuman
Country [48] 0 0
Austria
State/province [48] 0 0
Graz
Country [49] 0 0
Austria
State/province [49] 0 0
Innsbruck
Country [50] 0 0
Austria
State/province [50] 0 0
Linz
Country [51] 0 0
Austria
State/province [51] 0 0
Salzburg
Country [52] 0 0
Austria
State/province [52] 0 0
Vienna
Country [53] 0 0
Austria
State/province [53] 0 0
Wels
Country [54] 0 0
Belgium
State/province [54] 0 0
Atwerpen
Country [55] 0 0
Belgium
State/province [55] 0 0
Brussels
Country [56] 0 0
Belgium
State/province [56] 0 0
Bruxelles
Country [57] 0 0
Belgium
State/province [57] 0 0
Charleroi
Country [58] 0 0
Belgium
State/province [58] 0 0
Duffel
Country [59] 0 0
Belgium
State/province [59] 0 0
Edegem
Country [60] 0 0
Belgium
State/province [60] 0 0
Genk
Country [61] 0 0
Belgium
State/province [61] 0 0
Hasselt
Country [62] 0 0
Belgium
State/province [62] 0 0
Jette
Country [63] 0 0
Belgium
State/province [63] 0 0
Leuven
Country [64] 0 0
Belgium
State/province [64] 0 0
Liège
Country [65] 0 0
Belgium
State/province [65] 0 0
Namur
Country [66] 0 0
Brazil
State/province [66] 0 0
Minas Gerais
Country [67] 0 0
Brazil
State/province [67] 0 0
Rio Grande Do Sul
Country [68] 0 0
Brazil
State/province [68] 0 0
São Paulo
Country [69] 0 0
Brazil
State/province [69] 0 0
Rio de Janeiro
Country [70] 0 0
Canada
State/province [70] 0 0
Alberta
Country [71] 0 0
Canada
State/province [71] 0 0
British Columbia
Country [72] 0 0
Canada
State/province [72] 0 0
Nova Scotia
Country [73] 0 0
Canada
State/province [73] 0 0
Ontario
Country [74] 0 0
Canada
State/province [74] 0 0
Quebec
Country [75] 0 0
Canada
State/province [75] 0 0
Québec
Country [76] 0 0
China
State/province [76] 0 0
Guangdong
Country [77] 0 0
China
State/province [77] 0 0
Guangxi
Country [78] 0 0
China
State/province [78] 0 0
Hubei
Country [79] 0 0
China
State/province [79] 0 0
Jiangsu
Country [80] 0 0
China
State/province [80] 0 0
Jilin
Country [81] 0 0
China
State/province [81] 0 0
Sichuan
Country [82] 0 0
China
State/province [82] 0 0
Zhejiang
Country [83] 0 0
China
State/province [83] 0 0
Beijing
Country [84] 0 0
China
State/province [84] 0 0
Changsha
Country [85] 0 0
China
State/province [85] 0 0
Guangzhou
Country [86] 0 0
China
State/province [86] 0 0
Harbin
Country [87] 0 0
China
State/province [87] 0 0
Shanghai
Country [88] 0 0
China
State/province [88] 0 0
Tianjin
Country [89] 0 0
China
State/province [89] 0 0
Wuhan
Country [90] 0 0
Czechia
State/province [90] 0 0
Brno
Country [91] 0 0
Czechia
State/province [91] 0 0
Ostrava
Country [92] 0 0
Czechia
State/province [92] 0 0
Plzen
Country [93] 0 0
Czechia
State/province [93] 0 0
Praha 5
Country [94] 0 0
Czechia
State/province [94] 0 0
Praha 8
Country [95] 0 0
Czechia
State/province [95] 0 0
Usti nad Labem
Country [96] 0 0
Estonia
State/province [96] 0 0
Tallinn
Country [97] 0 0
Estonia
State/province [97] 0 0
Tartu
Country [98] 0 0
Finland
State/province [98] 0 0
Helsinki
Country [99] 0 0
Finland
State/province [99] 0 0
Oulu
Country [100] 0 0
Finland
State/province [100] 0 0
Tampere
Country [101] 0 0
Finland
State/province [101] 0 0
Turku
Country [102] 0 0
France
State/province [102] 0 0
Angers cedex 9
Country [103] 0 0
France
State/province [103] 0 0
Bayonne
Country [104] 0 0
France
State/province [104] 0 0
Beauvais
Country [105] 0 0
France
State/province [105] 0 0
Bethune Cedex
Country [106] 0 0
France
State/province [106] 0 0
Bordeaux
Country [107] 0 0
France
State/province [107] 0 0
Brest cedex
Country [108] 0 0
France
State/province [108] 0 0
Bron
Country [109] 0 0
France
State/province [109] 0 0
Caen
Country [110] 0 0
France
State/province [110] 0 0
Elbeuf
Country [111] 0 0
France
State/province [111] 0 0
Lille
Country [112] 0 0
France
State/province [112] 0 0
Limoges Cedex
Country [113] 0 0
France
State/province [113] 0 0
Lorient cedex
Country [114] 0 0
France
State/province [114] 0 0
Lyon cedex 08
Country [115] 0 0
France
State/province [115] 0 0
Lyon
Country [116] 0 0
France
State/province [116] 0 0
Marseille cedex 20
Country [117] 0 0
France
State/province [117] 0 0
Meaux
Country [118] 0 0
France
State/province [118] 0 0
Metz
Country [119] 0 0
France
State/province [119] 0 0
Montpellier
Country [120] 0 0
France
State/province [120] 0 0
Mulhouse Cedex
Country [121] 0 0
France
State/province [121] 0 0
Nantes
Country [122] 0 0
France
State/province [122] 0 0
Nice
Country [123] 0 0
France
State/province [123] 0 0
Nîmes
Country [124] 0 0
France
State/province [124] 0 0
Paris cedex 20
Country [125] 0 0
France
State/province [125] 0 0
Paris Cedex 5
Country [126] 0 0
France
State/province [126] 0 0
Paris
Country [127] 0 0
France
State/province [127] 0 0
Perpignan
Country [128] 0 0
France
State/province [128] 0 0
Périgueux cedex
Country [129] 0 0
France
State/province [129] 0 0
Reims
Country [130] 0 0
France
State/province [130] 0 0
Rennes Cedex 09
Country [131] 0 0
France
State/province [131] 0 0
Rouen
Country [132] 0 0
France
State/province [132] 0 0
Saint Herblain
Country [133] 0 0
France
State/province [133] 0 0
Saint-Priest en Jarez
Country [134] 0 0
France
State/province [134] 0 0
Saint-Quentin
Country [135] 0 0
France
State/province [135] 0 0
St Grégoire
Country [136] 0 0
France
State/province [136] 0 0
Toulon cedex 09
Country [137] 0 0
France
State/province [137] 0 0
Toulouse cedex 9
Country [138] 0 0
France
State/province [138] 0 0
Vannes
Country [139] 0 0
France
State/province [139] 0 0
Villefranche sur Saône
Country [140] 0 0
Germany
State/province [140] 0 0
Baden-Wuerttemberg
Country [141] 0 0
Germany
State/province [141] 0 0
Bayern
Country [142] 0 0
Germany
State/province [142] 0 0
Brandenburg
Country [143] 0 0
Germany
State/province [143] 0 0
Hessen
Country [144] 0 0
Germany
State/province [144] 0 0
Mecklenburg-Vorpommern
Country [145] 0 0
Germany
State/province [145] 0 0
Niedersachsen
Country [146] 0 0
Germany
State/province [146] 0 0
Nordrhein-Westfalen
Country [147] 0 0
Germany
State/province [147] 0 0
Rheinland-Pfalz
Country [148] 0 0
Germany
State/province [148] 0 0
Saarland
Country [149] 0 0
Germany
State/province [149] 0 0
Sachsen-Anhalt
Country [150] 0 0
Germany
State/province [150] 0 0
Sachsen
Country [151] 0 0
Germany
State/province [151] 0 0
Schleswig-Holstein
Country [152] 0 0
Germany
State/province [152] 0 0
Thueringen
Country [153] 0 0
Germany
State/province [153] 0 0
Berlin
Country [154] 0 0
Germany
State/province [154] 0 0
Bremen
Country [155] 0 0
Germany
State/province [155] 0 0
Hamburg
Country [156] 0 0
Greece
State/province [156] 0 0
Athens
Country [157] 0 0
Greece
State/province [157] 0 0
Chania
Country [158] 0 0
Greece
State/province [158] 0 0
Heraklion, Crete
Country [159] 0 0
Greece
State/province [159] 0 0
Larissa
Country [160] 0 0
Greece
State/province [160] 0 0
Marousi
Country [161] 0 0
Greece
State/province [161] 0 0
Neo Faliro
Country [162] 0 0
Greece
State/province [162] 0 0
Patra
Country [163] 0 0
Greece
State/province [163] 0 0
Piraeus
Country [164] 0 0
Greece
State/province [164] 0 0
Pylaia, Thessaloniki
Country [165] 0 0
Greece
State/province [165] 0 0
Thessaloniki
Country [166] 0 0
Hong Kong
State/province [166] 0 0
Kowloon
Country [167] 0 0
Hong Kong
State/province [167] 0 0
Shatin, N.T.
Country [168] 0 0
Hungary
State/province [168] 0 0
Budapest
Country [169] 0 0
Hungary
State/province [169] 0 0
Deszk
Country [170] 0 0
Hungary
State/province [170] 0 0
Gyula
Country [171] 0 0
Hungary
State/province [171] 0 0
Gyor
Country [172] 0 0
Hungary
State/province [172] 0 0
Miskolc
Country [173] 0 0
Hungary
State/province [173] 0 0
Mátraháza
Country [174] 0 0
Hungary
State/province [174] 0 0
Nyíregyháza
Country [175] 0 0
Hungary
State/province [175] 0 0
Pécs
Country [176] 0 0
Hungary
State/province [176] 0 0
Szombathely
Country [177] 0 0
Hungary
State/province [177] 0 0
Székesfehérvár
Country [178] 0 0
Hungary
State/province [178] 0 0
Zalaegerszeg-Pozva
Country [179] 0 0
India
State/province [179] 0 0
Ahemdabad
Country [180] 0 0
India
State/province [180] 0 0
Ahmedabad
Country [181] 0 0
India
State/province [181] 0 0
Bangalore
Country [182] 0 0
India
State/province [182] 0 0
Hyderabad
Country [183] 0 0
India
State/province [183] 0 0
Mumbai
Country [184] 0 0
Ireland
State/province [184] 0 0
Dublin
Country [185] 0 0
Ireland
State/province [185] 0 0
Galway
Country [186] 0 0
Israel
State/province [186] 0 0
Beer-Sheva
Country [187] 0 0
Israel
State/province [187] 0 0
Haifa
Country [188] 0 0
Israel
State/province [188] 0 0
Jerusalem
Country [189] 0 0
Israel
State/province [189] 0 0
Kfar Saba
Country [190] 0 0
Israel
State/province [190] 0 0
Ramat Gan
Country [191] 0 0
Israel
State/province [191] 0 0
Zrifin
Country [192] 0 0
Italy
State/province [192] 0 0
Campania
Country [193] 0 0
Italy
State/province [193] 0 0
Emilia-Romagna
Country [194] 0 0
Italy
State/province [194] 0 0
Friuli-Venezia-Giulia
Country [195] 0 0
Italy
State/province [195] 0 0
Lazio
Country [196] 0 0
Italy
State/province [196] 0 0
Liguria
Country [197] 0 0
Italy
State/province [197] 0 0
Lombardia
Country [198] 0 0
Italy
State/province [198] 0 0
Piemonte
Country [199] 0 0
Italy
State/province [199] 0 0
Puglia
Country [200] 0 0
Italy
State/province [200] 0 0
Sardegna
Country [201] 0 0
Italy
State/province [201] 0 0
Sicilia
Country [202] 0 0
Italy
State/province [202] 0 0
Toscana
Country [203] 0 0
Italy
State/province [203] 0 0
Umbria
Country [204] 0 0
Italy
State/province [204] 0 0
Veneto
Country [205] 0 0
Japan
State/province [205] 0 0
Aichi
Country [206] 0 0
Japan
State/province [206] 0 0
Chiba
Country [207] 0 0
Japan
State/province [207] 0 0
Ehime
Country [208] 0 0
Japan
State/province [208] 0 0
Fukuoka
Country [209] 0 0
Japan
State/province [209] 0 0
Hiroshima
Country [210] 0 0
Japan
State/province [210] 0 0
Hyogo
Country [211] 0 0
Japan
State/province [211] 0 0
Kanagawa
Country [212] 0 0
Japan
State/province [212] 0 0
Niigata
Country [213] 0 0
Japan
State/province [213] 0 0
Osaka
Country [214] 0 0
Japan
State/province [214] 0 0
Shizuoka
Country [215] 0 0
Japan
State/province [215] 0 0
Tokyo
Country [216] 0 0
Korea, Republic of
State/province [216] 0 0
Kyunggi-do
Country [217] 0 0
Korea, Republic of
State/province [217] 0 0
Seongnam-si Gyeonggi-do
Country [218] 0 0
Korea, Republic of
State/province [218] 0 0
Seoul
Country [219] 0 0
Netherlands
State/province [219] 0 0
Amsterdam
Country [220] 0 0
Netherlands
State/province [220] 0 0
Harderwijk
Country [221] 0 0
Netherlands
State/province [221] 0 0
Heerlen
Country [222] 0 0
Netherlands
State/province [222] 0 0
Leeuwarden
Country [223] 0 0
Netherlands
State/province [223] 0 0
Nieuwegein
Country [224] 0 0
Norway
State/province [224] 0 0
Oslo
Country [225] 0 0
Norway
State/province [225] 0 0
Trondheim
Country [226] 0 0
Poland
State/province [226] 0 0
Bialystok
Country [227] 0 0
Poland
State/province [227] 0 0
Bydgoszcz
Country [228] 0 0
Poland
State/province [228] 0 0
Checiny
Country [229] 0 0
Poland
State/province [229] 0 0
Gdansk
Country [230] 0 0
Poland
State/province [230] 0 0
Glucholazy
Country [231] 0 0
Poland
State/province [231] 0 0
Krakow
Country [232] 0 0
Poland
State/province [232] 0 0
Lodz
Country [233] 0 0
Poland
State/province [233] 0 0
Lublin
Country [234] 0 0
Poland
State/province [234] 0 0
Poznan
Country [235] 0 0
Poland
State/province [235] 0 0
Rzeszow
Country [236] 0 0
Poland
State/province [236] 0 0
Szczecin
Country [237] 0 0
Poland
State/province [237] 0 0
Warszawa
Country [238] 0 0
Poland
State/province [238] 0 0
Wroclaw
Country [239] 0 0
Poland
State/province [239] 0 0
Zakopane
Country [240] 0 0
Russian Federation
State/province [240] 0 0
Chelyabinsk
Country [241] 0 0
Russian Federation
State/province [241] 0 0
Kazan
Country [242] 0 0
Russian Federation
State/province [242] 0 0
Kursk
Country [243] 0 0
Russian Federation
State/province [243] 0 0
Moscow
Country [244] 0 0
Russian Federation
State/province [244] 0 0
St. Petersburg
Country [245] 0 0
Russian Federation
State/province [245] 0 0
Stavropol
Country [246] 0 0
Russian Federation
State/province [246] 0 0
Ufa,
Country [247] 0 0
Singapore
State/province [247] 0 0
Singapore
Country [248] 0 0
Spain
State/province [248] 0 0
Barcelona
Country [249] 0 0
Spain
State/province [249] 0 0
Granada
Country [250] 0 0
Spain
State/province [250] 0 0
Leganes
Country [251] 0 0
Spain
State/province [251] 0 0
Lerida
Country [252] 0 0
Spain
State/province [252] 0 0
Madrid
Country [253] 0 0
Spain
State/province [253] 0 0
Málaga
Country [254] 0 0
Spain
State/province [254] 0 0
Oviedo
Country [255] 0 0
Spain
State/province [255] 0 0
Sabadell (Barcelona)
Country [256] 0 0
Spain
State/province [256] 0 0
San Sebastian de los Reyes
Country [257] 0 0
Spain
State/province [257] 0 0
Santander
Country [258] 0 0
Spain
State/province [258] 0 0
Santiago de Compostela
Country [259] 0 0
Spain
State/province [259] 0 0
Sevilla
Country [260] 0 0
Spain
State/province [260] 0 0
Valencia
Country [261] 0 0
Sweden
State/province [261] 0 0
Lund
Country [262] 0 0
Sweden
State/province [262] 0 0
Stockholm
Country [263] 0 0
Sweden
State/province [263] 0 0
Uppsala
Country [264] 0 0
Switzerland
State/province [264] 0 0
Aarau
Country [265] 0 0
Switzerland
State/province [265] 0 0
Basel
Country [266] 0 0
Switzerland
State/province [266] 0 0
Bern
Country [267] 0 0
Switzerland
State/province [267] 0 0
Bruderholz
Country [268] 0 0
Switzerland
State/province [268] 0 0
Thun
Country [269] 0 0
Switzerland
State/province [269] 0 0
Zuerich
Country [270] 0 0
Taiwan
State/province [270] 0 0
Kaohsiung
Country [271] 0 0
Taiwan
State/province [271] 0 0
Taichung
Country [272] 0 0
Taiwan
State/province [272] 0 0
Tainan
Country [273] 0 0
Taiwan
State/province [273] 0 0
Taipei
Country [274] 0 0
Taiwan
State/province [274] 0 0
Taoyuan County
Country [275] 0 0
Thailand
State/province [275] 0 0
Bangkok
Country [276] 0 0
Thailand
State/province [276] 0 0
Chiang Mai
Country [277] 0 0
Thailand
State/province [277] 0 0
Hatyai, Songkhla
Country [278] 0 0
Ukraine
State/province [278] 0 0
Dnipropetrovsk
Country [279] 0 0
Ukraine
State/province [279] 0 0
Donetsk
Country [280] 0 0
Ukraine
State/province [280] 0 0
Kharkiv
Country [281] 0 0
Ukraine
State/province [281] 0 0
Kyiv
Country [282] 0 0
Ukraine
State/province [282] 0 0
Lviv
Country [283] 0 0
Ukraine
State/province [283] 0 0
Odesa
Country [284] 0 0
Ukraine
State/province [284] 0 0
Simferopol
Country [285] 0 0
Ukraine
State/province [285] 0 0
Uzhgorod
Country [286] 0 0
Ukraine
State/province [286] 0 0
Vinnytsia
Country [287] 0 0
United Kingdom
State/province [287] 0 0
Cambridgeshire
Country [288] 0 0
United Kingdom
State/province [288] 0 0
Greater Manchester
Country [289] 0 0
United Kingdom
State/province [289] 0 0
Leicestershire
Country [290] 0 0
United Kingdom
State/province [290] 0 0
Midlothian
Country [291] 0 0
United Kingdom
State/province [291] 0 0
Surrey
Country [292] 0 0
United Kingdom
State/province [292] 0 0
Aberdeen
Country [293] 0 0
United Kingdom
State/province [293] 0 0
Bebington, Wirral
Country [294] 0 0
United Kingdom
State/province [294] 0 0
Belfast
Country [295] 0 0
United Kingdom
State/province [295] 0 0
Birmingham
Country [296] 0 0
United Kingdom
State/province [296] 0 0
Cambridge
Country [297] 0 0
United Kingdom
State/province [297] 0 0
Dundee
Country [298] 0 0
United Kingdom
State/province [298] 0 0
Glasgow
Country [299] 0 0
United Kingdom
State/province [299] 0 0
Inverness
Country [300] 0 0
United Kingdom
State/province [300] 0 0
Leeds
Country [301] 0 0
United Kingdom
State/province [301] 0 0
Liverpool
Country [302] 0 0
United Kingdom
State/province [302] 0 0
London
Country [303] 0 0
United Kingdom
State/province [303] 0 0
Maidstone
Country [304] 0 0
United Kingdom
State/province [304] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic
product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of
their tumor. A course of 13 injections will be administered over 27 months. The Protocol
Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Trial website
https://clinicaltrials.gov/show/NCT00480025
Trial related presentations / publications
Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Jun;17(6):822-835. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT00480025